Overexpression of TDP-43 causes partially p53-dependent G2/M arrest and p53-independent cell death in HeLa cells

Neuroscience Letters

Volumn 506, Issue 2, 2012, Pages 271-276

  Lee, Kikyo ^a,b   Suzuki, Hiroaki ^a   Aiso, Sadakazu ^b   Matsuoka, Masaaki ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ALS; Cell cycle; FTLD U; Non neuron autonomous toxicity; P53; TDP 43

Indexed keywords

PROTEIN P53; TAR DNA BINDING PROTEIN;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DATA ANALYSIS; GAIN OF FUNCTION MUTATION; GLIA CELL; HELA CELL; HUMAN; HUMAN CELL; NERVE CELL; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM;

BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL SEPARATION; DNA-BINDING PROTEINS; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINTS; HELA CELLS; HUMANS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84655163935     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.11.021     Document Type: Article

References (23)

1. Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006, 351:602-611.
2. Boillée S., Vande Velde C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
3. Brandmeir N.J., Geser F., Kwong L.K., Zimmerman E., Qian J., Lee V.M., Trojanowski J.Q. Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease. Acta Neuropathol. 2008, 115:123-131.
4. Chen-Plotkin A.S., Lee V.M., Trojanowski J.Q. TAR DNA-binding protein 43 in neurodegenerative disease. Nat. Rev. Neurol. 2010, 6:211-220.
5. Gendron T.F., Josephs K.A., Petrucelli L. Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration. Neuropathol. Appl. Neurobiol. 2010, 36:97-112.
6. Hayashi Y., Kashiwagi K., Yoshikawa K. Protease inhibitors generate cytotoxic fragments from Alzheimer amyloid protein precursor in cDNA-transfected glioma cells. Biochem. Biophys. Res. Commun. 1992, 187:1249-1255.
7. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009, 187:761-772.
8. Kasai T., Tokuda T., Ishigami N., Sasayama H., Foulds P., Mitchell D.J., Mann D.M., Allsop D., Nakagawa D. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009, 117:55-62.
9. Lagier-Tourenne C., Polymenidou M., Cleveland D.W. TDP-43, FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 2010, 19(R1):R46-R64.
10. Mishra M., Paunesku T., Woloschak G.E., Siddique T., Zhu L.J., Lin S., Greco K., Bigio E.H. Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol. 2007, 114:81-94.
11. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
12. Nishihira Y., Tan C.F., Onodera O., Toyoshima Y., Yamada M., Morita T., Nishizawa M., Kakita A., Takahashi H. Sporadic amyotrophic lateral sclerosis: two pathological patterns shown by analysis of distribution of TDP-43-immunoreactive neuronal and glial cytoplasmic inclusions. Acta Neuropathol. 2008, 116:169-182.
13. Rabinovici G.D., Miller B.L. Frontotemporal lobar degeneration epidemiology, pathophysiology, diagnosis and management. CNS Drugs 2010, 24:375-398.
14. Rothstein J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 2009, 65(Suppl. 1):S3-S9.
15. Shiwaku H., Yoshimura N., Tamura T., Sone M., Ogishima S., Watase K., Tagawa K., Okazawa H. Suppression of the novel ER protein Maxer by mutant ataxin-1 in Bergman glia contributes to non-cell-autonomous toxicity. EMBO J. 2010, 29:2446-2460.
16. Silva G.A., Feeney C., Mills L.R., Theriault E. A novel and rapid method for culturing pure rat spinal cord astrocytes on untreated glass. J. Neurosci. Methods 1998, 80:75-79.
17. Suzuki H., Kurita M., Mizumoto K., Nishimoto I., Ogata E., Matsuoka M. p19ARF-induced p53-independent apoptosis largely occurs through BAX. Biochem. Biophys. Res. Commun. 2003, 312:1273-1277.
18. Suzuki H., Lee K., Matsuoka M. TDP-43-induced death is associated with altered regulation of BIM and BCL-XL and attenuated by caspase-mediated TDP-43 cleavage. J. Biol. Chem. 2011, 286:13171-13183.
19. H. Suzuki, M. Matsuoka, TDP-43 toxicity is mediated by the unfolded protein response-unrelated induction of C/EBP homologous protein expression, J. Neurosci. Res., in press.
20. Suzuki M., Mikami H., Watanabe T., Yamano T., Yamazaki T., Nomura M., Yasui K., Ishikawa H., Ono S. Increased expression of TDP-43 in the skin of amyotrophic lateral sclerosis. Acta Neurol. Scand. 2010, 122:367-372.
21. Takahashi S., Saito S., Ohtani N., Sakai T. Involvement of the Oct-1 regulatory element of the gadd45 promoter in the p53-independent response to ultraviolet irradiation. Cancer Res. 2001, 61:1187-1195.
22. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815.
23. Wang D.B., Gitcho M.A., Kraemer B.C., Klein R.L. Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis. Eur. J. Neurosci. 2011, 34:1179-1188.